Burning Rock Biotech (NASDAQ:BNR) Announces Earnings Results

Burning Rock Biotech (NASDAQ:BNR) issued its quarterly earnings results on Tuesday. The company reported ($1.08) EPS for the quarter, Zacks reports. Burning Rock Biotech had a negative return on equity of 60.68% and a negative net margin of 83.50%.

Burning Rock Biotech Price Performance

NASDAQ BNR opened at $5.67 on Tuesday. The company has a market capitalization of $58.03 million, a P/E ratio of -1.89 and a beta of 0.55. Burning Rock Biotech has a 12 month low of $2.62 and a 12 month high of $8.99. The company’s 50 day simple moving average is $6.32 and its 200 day simple moving average is $5.28.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.